Current Trends on Applications of Stem Cells in Diabetic Nephropathy

Scientists review the potential mechanism of stem cells as new therapeutic agents in the treatment of diabetic nephropathy (DN). They also review recent findings and updated information about not only the utilization of stem cells on DN in both preclinical and clinical trials but limitations and future expectations of stem cell-based therapy for DN.
[Cell Death & Disease]
Liu, D., Zheng, W., Pan, S., & Liu, Z. (2020). Concise review: current trends on applications of stem cells in diabetic nephropathy. Cell Death & Disease, 11(11), 1–14. https://doi.org/10.1038/s41419-020-03206-1 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Regulatory T Cell Therapy following Liver Transplantation

The authors summarize the discovery and development of Tregs, and discuss the outstanding challenges of Treg cell therapy and its future prospects for routine use in liver transplantation.
[Liver Transplantation]
Regulatory T Cell Therapy Following Liver Transplantation - Yu - - Liver Transplantation - Wiley Online Library. (n.d.). Retrieved November 24, 2020, from https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/lt.25948 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Chemical Mutagenesis of a Gpcr Ligand: Detoxifying “Inflammo-Attraction” to Direct Therapeutic Stem Cell Migration

When co-administered with transplanted human induced pluripotent stem cell-derived human neural stem cells in a mouse model of a prototypical neurodegenerative disease, the agonist enhanced migration, dissemination, and integration of donor-derived cells into the diseased cerebral cortex where their secreted cross-corrective enzyme mediated a therapeutic impact unachieved by cells alone.
[Proceedings of the National Academy of Sciences of the United States of America]
Lee, J.-P., Zhang, R., Yan, M., Duggineni, S., Wakeman, D. R., Niles, W. L., Feng, Y., Chen, J., Hamblin, M. H., Han, E. B., Gonzalez, R., Fang, X., Zhu, Y., Wang, J., Xu, Y., Wenger, D. A., Seyfried, T. N., An, J., Sidman, R. L., … Snyder, E. Y. (2020). Chemical mutagenesis of a GPCR ligand: Detoxifying “inflammo-attraction” to direct therapeutic stem cell migration. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1911444117 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Casting a Wider Protective Net: Anti-Infective Vaccine Strategies for Patients with Hematologic Malignancy and Blood and Marrow Transplantation

The authors summarize current vaccine recommendations for patients with hematologic malignancies including patients who undergo hematopoietic cell transplant.
[Blood Reviews]
McMasters, M., Blair, B. M., Lazarus, H. M., & Alonso, C. D. (2020). Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation. Blood Reviews, 100779. https://doi.org/10.1016/j.blre.2020.100779 Cite
Abstract
Bookmark

No account yet? Register

0
Share

The Intrinsic Immunogenic Properties of Cancer Cell Lines, Immunogenic Cell Death, and How These Influence Host Antitumor Immune Responses

Scientists discuss the immunostimulatory and immunosuppressive properties of cancer cell lines commonly used in immunogenic cell death studies being apoptosis or necroptosis.
[Cell Death & Differentiation]
Aaes, T. L., & Vandenabeele, P. (2020). The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses. Cell Death & Differentiation, 1–18. https://doi.org/10.1038/s41418-020-00658-y Cite
Abstract
Bookmark

No account yet? Register

0
Share

Helixmith Announces First Patient Enrolled in Phase III Study of Engensis

Helixmith announced enrollment of the first patient in a second Phase III clinical trial targeting diabetic peripheral neuropathy (DPN), REGAiN-1A, using Helixmith’s flagship gene therapy product Engensis REGAiN-1A has an initial target enrollment of 152 DPN patients at approximately 15 clinical sites across the US.
[Helixmith]
Press Release
Bookmark

No account yet? Register

0
Share

EpOMEs Act As Immune Suppressors in a Lepidopteran Insect, Spodoptera exigua

Among 139 S. exigua CYPs, an ortholog to human EpOME synthase was predicted and its expression was highly inducible upon bacterial challenge. RNA interference of SE51385 prevented down-regulation of immune responses at a late stage following bacterial challenge.
[Scientific Reports]
Vatanparast, M., Ahmed, S., Lee, D.-H., Hwang, S. H., Hammock, B., & Kim, Y. (2020). EpOMEs act as immune suppressors in a lepidopteran insect, Spodoptera exigua. Scientific Reports, 10(1), 20183. https://doi.org/10.1038/s41598-020-77325-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Enhanced CAR-T Activity against Established Tumors by Polarizing Human T Cells to Secrete Interleukin-9

Researchers demonstrated that human CAR-T cells polarized and expanded under a Th9-culture condition have an enhanced antitumor activity against established tumors.
[Nature Communications]
Liu, L., Bi, E., Ma, X., Xiong, W., Qian, J., Ye, L., Su, P., Wang, Q., Xiao, L., Yang, M., Lu, Y., & Yi, Q. (2020). Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nature Communications, 11(1), 5902. https://doi.org/10.1038/s41467-020-19672-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Identification of Natural CRISPR Systems and Targets in the Human Microbiome

Scientists profiled CRISPR loci and cas genes in the body-wide human microbiome using 2,355 metagenomes, yielding functional and taxonomic profiles for 2.9 million spacers by aligning the spacer content to each sample’s metagenome and corresponding gene families.
[Cell Host & Microbe]
Münch, P. C., Franzosa, E. A., Stecher, B., McHardy, A. C., & Huttenhower, C. (2020). Identification of Natural CRISPR Systems and Targets in the Human Microbiome. Cell Host & Microbe, 0(0). https://doi.org/10.1016/j.chom.2020.10.010 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Investigators report the outcome of 51 r/r B-ALL patients from a non-randomized, Phase II clinical trial. The primary outcome showed that the overall remission rate was 80.9%.
[Nature Communications]
An, F., Wang, H., Liu, Z., Wu, F., Zhang, J., Tao, Q., Li, Y., Shen, Y., Ruan, Y., Zhang, Q., Pan, Y., Zhu, W., Qin, H., Wang, Y., Fu, Y., Feng, Z., & Zhai, Z. (2020). Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nature Communications, 11(1), 5928. https://doi.org/10.1038/s41467-020-19774-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

MEK Inhibition Reprograms CD8+ T Lymphocytes Into Memory Stem Cells with Potent Antitumor Effects

Scientists found that MEK1/2 inhibition induced stem cell–like memory T cells that have naive phenotype with self-renewability, enhanced multipotency and proliferative capacity.
[Nature Immunology]
MEK inhibition reprograms CD8 + T lymphocytes into memory stem cells with potent antitumor effects | Nature Immunology. (n.d.). Retrieved November 23, 2020, from https://www.nature.com/articles/s41590-020-00818-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share